Capricor Therapeutics (CAPR) Cash & Equivalents (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Cash & Equivalents of $105.4 million for Q1 2026, up 266.12% year-over-year from $28.8 million in Q1 2025, and down 63.38% quarter-over-quarter from $287.8 million in Q4 2025.
Capricor Therapeutics (CAPR) Cash & Equivalents (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $105.4 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 266.12% year-over-year to $105.4 million; the TTM figure through Mar 2026 stood at $105.4 million (up 266.12% YoY), while the FY2025 annual figure was $287.8 million, up 2450.26% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $105.4 million, down from $287.8 million in the prior quarter.
- The five-year high for Cash & Equivalents was $287.8 million in Q4 2025, with the low at $6.2 million in Q1 2024.
- The 5-year median for Cash & Equivalents is $14.7 million (2023), against an average of $41.1 million.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 81.81% in 2023, then soared 2450.26% in 2025.
- Capricor Therapeutics' Cash & Equivalents stood at $9.6 million in 2022, then soared by 53.02% to $14.7 million in 2023, then decreased by 23.19% to $11.3 million in 2024, then jumped by 2450.26% to $287.8 million in 2025, then tumbled by 63.38% to $105.4 million in 2026.
- Business Quant data shows CAPR's Cash & Equivalents at $105.4 million in Q1 2026, $287.8 million in Q4 2025, and $19.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 105.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.42 Mn |
| Dec 31, 2025 | 287.85 Mn |
| Sep 30, 2025 | 19.51 Mn |
| Jun 30, 2025 | 23.24 Mn |
| Mar 31, 2025 | 28.79 Mn |
| Dec 31, 2024 | 11.29 Mn |
| Sep 30, 2024 | 68.38 Mn |
| Jun 30, 2024 | 10.69 Mn |
| Mar 31, 2024 | 6.21 Mn |
| Dec 31, 2023 | 14.69 Mn |
| Sep 30, 2023 | 8.98 Mn |
| Jun 30, 2023 | 9.84 Mn |
| Mar 31, 2023 | 10.61 Mn |
| Dec 31, 2022 | 9.60 Mn |
| Sep 30, 2022 | 8.41 Mn |
| Jun 30, 2022 | 16.39 Mn |
| Mar 31, 2022 | 58.30 Mn |
| Dec 31, 2021 | 34.89 Mn |
| Sep 30, 2021 | 40.80 Mn |
| Jun 30, 2021 | 38.10 Mn |